Clinical Pharmacology And Population Pharmacokinetic/Pharmacodynamic Modeling of Lectin Pathway Inhibition by Narsoplimab (OMS721)

被引：0

作者：

Pullman, William ^{[1
]}

Facius, Axel ^{[2
]}

Lahu, Gezim ^{[2
]}

Smyth, Brendan ^{[1
]}

机构：

[1] Omeros Corp, Seattle, WA USA

[2] ThinkQ2 AG, Baar, Switzerland

来源：

BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

P142

引用

页码：300 / 301

页数：2

共 13 条

[1] Development of Pharmacodynamic Assays to Assess Ex Vivo Masp-2 Inhibition and Their Use to Characterize the Pharmacodynamics of Narsoplimab (OMS721) in Humans and Monkeys
Freeman, Jeremy
Cummings, Jason
Chuidian, Marither
Dudler, Thomas
BLOOD, 2020, 136
[2] Development of pharmacodynamic assays to assess ex vivo MASP-2 inhibition and their use to characterize the pharmaco-dynamics of narsoplimab (OMS721) in humans and monkeys
Freeman, Jeremy
Cummings, Jason
Dudler, Thomas
MOLECULAR IMMUNOLOGY, 2022, 141 : 167 - 168
[3] Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
Rajendra S. Kadam
Johannes N. Van Den Anker
Clinical Pharmacokinetics, 2016, 55 : 1031 - 1043
[4] Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
Kadam, Rajendra S.
Van den Anker, Johannes N.
CLINICAL PHARMACOKINETICS, 2016, 55 (09) : 1031 - 1043
[5] Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: Modeling interoccasion pharmacodynamic variability
Hong, Ying
Mager, Donald E.
Blum, Robert A.
Jusko, William J.
PHARMACEUTICAL RESEARCH, 2007, 24 (06) : 1088 - 1097
[6] Population Pharmacokinetic/Pharmacodynamic Modeling of Systemic Corticosteroid Inhibition of Whole Blood Lymphocytes: Modeling Interoccasion Pharmacodynamic Variability
Ying Hong
Donald E. Mager
Robert A. Blum
William J. Jusko
Pharmaceutical Research, 2007, 24 : 1088 - 1097
[7] Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population
Maglalang, Patricia D.
Wen, Jiali
Hornik, Christoph P.
Gonzalez, Daniel
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
[8] Clinical pharmacology of asparaginases in the United States: Asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients
Avramis, Vassilios I.
Spence, Susan A.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (04) : 239 - 247
[9] CLINICAL-PHARMACOLOGY OF RECOMBINANT HUMAN FOLLICLE-STIMULATING-HORMONE .3. PHARMACOKINETIC-PHARMACODYNAMIC MODELING AFTER REPEATED SUBCUTANEOUS ADMINISTRATION
PORCHET, HC
LECOTONNEC, JY
LOUMAYE, E
FERTILITY AND STERILITY, 1994, 61 (04) : 687 - 695
[10] Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of etanercept in patients with juvenile rheumatoid arthritis (JRA) using a dichotomous clinical endpoint.
Yim, D
Zhou, H
Peck, CC
Lee, H
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P92 - P92

← 1 2 →